UNSPSC 51262501: Betanidine or bethanidine

This classification denotes an adrenergic antagonist with the molecular formula C10H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8S3YM7AUU, chemically known as 2-benzyl-1,3-dimethylguanidine but generally known as betanidine, which bears US NIH Compound Identifier 2368. Betanidine most often comes in base and sulfate forms. European Medicines Agency schedules Betanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05801MIG. The term BETANIDINE is an International Non-Proprietary Name.

UNSPSC 51262501 Betanidine or bethanidine is a Commodity code that in practice covers pharmaceutical products procured by state and local health agencies, though the recent sourcing activity identified under this code does not align with the nominal scope. Seminole County, Florida's IFB60459723LAS solicitation, posted in June 2026, requests naloxone and safe drug deactivation systems—opioid-reversal medications and harm-reduction equipment—rather than bethanidine, an antihypertensive agent. The mismatch suggests either a tagging error in the county's procurement system or a significant divergence between the code's intended pharmaceutical classification and how local health departments are using it operationally. The county's procurement is structured as a competitive bidding IFB with a two-year initial term and one-year renewal option, quarterly deliveries to a single county health facility, and standard compliance requirements including E-Verify, drug-free workplace certification, and potential FEMA funding implications.

Activity under this code appears sparse in the recent state and local solicitation record, with no other opportunities visible beyond the Seminole County posting. That single Florida-sourced opportunity is the only recent state or local activity available to characterize issuing-body patterns or geographic concentration. The Seminole County solicitation closed on July 26, 2023 (with a posting date of June 30, 2026, creating an internal date inconsistency in the source data), specifying annual volumes of 1,900 units of naloxone and 800 deactivation systems at quarterly intervals. Vendors must submit pricing on a fixed-fee basis, handle all shipping costs, and carry workers' compensation and commercial general liability insurance. Given the limited recent activity and the nominal-versus-actual scope mismatch, pursuit under this code warrants verification that the Commodity classification aligns with your firm's actual product lines and distribution capability.